Cochrane Evidence Synthesis and Methods ►

Prognostic models for colorectal cancer incidence and mortality in patients with inflammatory bowel disease

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:

Primary objectives

The primary objectives are to identify, describe, and appraise all prognostic models developed to predict colorectal cancer incidence or mortality in patients with IBD, at any time point after the clinical diagnosis of IBD, and if possible meta-analyse their predictive performances.

Investigation of sources of heterogeneity between studies

Sources of heterogeneity to be investigated comprise differences in the definition of colorectal dysplasia, colorectal cancer and IBD, the type of IBD investigated, study design, time point for prognostication after the clinical diagnosis of IBD, time horizon for outcome measurements, length of follow-up, and statistical analysis applied (Debray 2017).

This is a protocol.

Published:

25 January 2023

Authors:

Gantzel R, Wieszczy P, Refsum E, Jess T, Larsen L, Bretthauer M, Vandvik PO, Blom J, Erichsen R, Kalager M, Helsingen L

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Gantzel R, Wieszczy P, Refsum E, Jess T, Larsen L, Bretthauer M, Vandvik PO, Blom J, Erichsen R, Kalager M, Helsingen L. Prognostic models for colorectal cancer incidence and mortality in patients with inflammatory bowel disease (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 1. Art. No.: CD015434. DOI: 10.1002/14651858.CD015434.